Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | APAF1 | O14727 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | POLB | P06746 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | HPGD | P15428 | 1/20 | 0.75 |
| ▸ | UBE2N | P61088 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminodimethoxyquinazolinylpiperazine SCHEMBL32690190 | 0.86 | KDM4E (1.00) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| Aminodimethoxyquinazolinylpiperazine SCHEMBL608966 | 0.86 | KDM4E (1.00) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| Aminodimethoxyquinazolinylpiperazine SCHEMBL11079651 | 0.85 | POLB (0.97) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| SCHEMBL10625589 | 0.84 | KDM4E (0.53) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| SCHEMBL7796182 | 0.81 | KDM4E (0.90) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| Hydrochloric Acid SCHEMBL11475168 | 0.81 | POLB (0.88) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| SCHEMBL11165343 | 0.79 | KDM4E (0.81) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| SCHEMBL2920903 | 0.78 | CHRNB2 (0.46) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| SCHEMBL15218289 | 0.76 | KDM4E (0.76) | KDM4EAPAF1ALDH1A1POLBMAPT | |
| SCHEMBL13191126 | 0.76 | KDM4E (0.76) | KDM4EAPAF1ALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200222405-A1 | PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND THEIR USES | CASE WESTERN RESERVE UNIVERSITY | 2020-07-16 | — | — | US | disclosed |
| WO-2019010180-A1 | PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND THEIR USES | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200222405-A1 | PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND THEIR USES | EPHA1, EPHA7, EPHA3 | KDM4E 4515/4885APAF1 188/4885ALDH1A1 3504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.